Qualitative and Quantitative Analysis of Gentamicin Sulfate and Related Impurities on ACQUITY UPLC with QDa

Importance of the Topic

Gentamicin sulfate is a critical aminoglycoside antibiotic composed of multiple active components and structurally similar impurities. Accurate identification and quantification of both major constituents and trace-level impurities are essential for ensuring drug safety, therapeutic efficacy, and compliance with regulatory standards.

Aims and Overview of the Study

This study describes the development of a rapid, robust UPLC-MS method for simultaneous qualitative and quantitative analysis of gentamicin sulfate and its related impurities. The approach leverages an ACQUITY UPLC H-Class System coupled with an ACQUITY QDa Detector to separate five principal gentamicin components (C1, C1a, C2, C2a, C2b) along with sisomicin, garamine, G-418, and gentamicin A/B within a 35-minute runtime.

Methodology and Instrumentation

The chromatographic method employed an Atlantis T3 column (4.6 × 150 mm, 3 µm) under a gradient from aqueous 0.2% TFA (pH 2.3) mixed with acetonitrile/isopropanol to methanol:

• Flow rate: 0.6 mL/min
• Column temperature: 25 °C; sample temperature: 5 °C
• Injection volume: 1 µL
• Gradient: 100% aqueous for 18 min, linear to 100% methanol by 20 min, hold to 25 min, and re-equilibrate to 35 min

The ACQUITY QDa Detector operated in positive ESI mode (150–1000 m/z), capillary 0.8 kV, cone voltage 10 V, sampling rate 1 pt/sec. Data acquisition and processing were performed with Empower 3 CDS.

Results and Discussion

System suitability met or exceeded USP/EP criteria:

• Resolution: sisomicin/C1a 1.3 (>1.2); C2/C2b 2.3 (>1.5)
• Signal-to-noise >20 for sisomicin at 0.1 µg/mL

Quantitative performance:

• LOD/LOQ for sisomicin: 0.03 µg/mL (S/N=9) and 0.1 µg/mL (S/N=27)
• Linearity over 0.15–1.5 µg/mL, R²=0.998
• Reproducibility: %RSD <5% for eight analytes
• Recovery: 105.96% for sisomicin spiked at 20 µg/mL

All five gentamicin components and impurities were baseline-resolved within 35 minutes, confirming method robustness.

Benefits and Practical Applications of the Method

This UPLC-QDa platform provides:

• High throughput analysis with minimal runtime
• Selective, sensitive detection of non-UV-active aminoglycosides without derivatization
• Accurate quantification for pharmaceutical quality control and regulatory submissions

Future Trends and Potential Applications

Future enhancements may include integration of compact MS detectors for real-time process monitoring, automated impurity profiling workflows, and coupling with UHPLC for further runtime reduction. Advanced data analytics and machine learning can further improve method robustness and QC efficiency.

Conclusion

A validated UPLC-QDa method was established for comprehensive qualitative and quantitative analysis of gentamicin sulfate and its related impurities. The method fulfills regulatory criteria for resolution, sensitivity, and reproducibility, supporting its application in pharmaceutical quality assurance.

Reference

1. Jammal N., AL-Mardini M.A. Development and Validation of LC-MS Method for the Estimation of Gentamicin Sulfate and its Impurities in Injections. Int. J. Pharm. Sci. Rev. Res. 2014, 27(1), 70–73.
2. Grahneka R., Zupancic-Kralj L. Identification of Gentamicin Impurities by LC-MS/MS. J. Pharm. Biomed. Anal. 2009, 50(5), 1037–1043.
3. European Pharmacopoeia. Gentamicin Sulphate. 2014, 8.1, 2326–2382.
4. United States Pharmacopeia. Gentamicin Sulfate USP 37–NF32, 3138–3139.